Highlights Percheron Therapeutics Limited BOERSE MUENCHEN

Equities

AWY0

AU0000317281

Market Closed - BOERSE MUENCHEN Other stock markets 03:43:05 2024-07-05 pm EDT			5-day change	1st Jan Change
0.0504 ^EUR	0.00%		+3.70%	+46.51%

Jun. 17	Percheron Therapeutics Appoints CFO	MT
Jun. 03	Percheron Therapeutics Names Chief Medical Advisor	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	May. 28	MT
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	May. 19	MT
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	May. 05	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	23-06-27	CI
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	23-03-13	CI
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	23-02-14	MT
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	23-02-13	CI
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency	23-02-12	CI
Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD	23-01-31	CI
Antisense Therapeutics Files Trial Applications for Phase 2b Trial	22-12-19	MT
Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe	22-12-18	CI
Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron	22-11-13	CI
Antisense Therapeutics Receives R&D Rebate of Nearly $580,000	22-10-14	MT
Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer	22-10-04	CI
Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study	22-09-11	CI
Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase	22-09-06	CI
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Percheron Therapeutics Limited BOERSE MUENCHEN

Equities

AWY0

AU0000317281

Highlights

Filters